Uterine Fibroids

Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.

A recent study reveals that relugolix combination therapy demonstrates sustained reduction in menstrual bleeding volume for women with symptomatic uterine fibroids.

In a recent study, improvements in symptom severity and quality of life scores at years 1, 2, and 3 were seen in patients receiving hysterectomy, myomectomy, or uterine artery embolization.

Reductions in symptom incidence and severity from uterine fibroids and endometriosis have been observed in patients receiving relugolix combination therapy.

In a recent study, larger fibroid sizes and location in the lower uterine segment or cervix were associated with greater odds of post partum hemorrhage requiring packed red blood cell transfusion.

In a recent study, uterine fibroids were significantly associated affecting patient who are Black or Asian-Chinese and over 35 years of age.

In a recent study, women with symptomatic uterine fibroids saw reduced symptom burden and improved quality of life after 24 weeks of treatment through relugolix combination therapy.

Women with symptomatic uterine fibroids achieved a greater improvement in quality of life with myomectomy than with uterine artery embolization (UAE), according to a randomized study published in the journal Health Technology Assessment.

A study published in Women’s Health Reports offers deeper knowledge of women’s lived experience with fibroids in their own words, and confirms the burden of the disease.

A prospective study published in the International Scientific Research Journal has found that colposcopy was able to detect exoservicitis in about one-third of women with uterine fibroids.

The US Food and Drug Administration has accepted to review the supplemental New Drug Application for Myfembree for the potential treatment of heavy menstrual bleeding associated with uterine fibroids for up to 2 years.

Vitamins and diet can play a role in the prevention and treatment of uterine fibroids, according to a literature review spanning 20 years published in the journal Nutrients.

A call to action in the journal Reproductive Sciences hopes to empower health care providers to optimize their quality of care for women with uterine fibroids by relying on the best available evidence and best patient-centered practices.

Enhanced recovery after surgery (ERAS) programs could help reduce hospitalization time, costs, and opioid use.

Among minimally invasive treatments for uterine fibroids, uterine artery embolization (UAE) produces greater fibroid shrinkage and more complications than MRI-guided HIFU (MRIgHIFU), according to a study in BMC Women’s Health.

Women with uterine fibroids (UF) experience higher rates of depression, anxiety, and self-directed violence, especially those with pain or who have had a hysterectomy, according to a study published in the Journal of Epidemiology and Community Health.

“Although traditional surgical treatments can resolve the clinical symptoms, they have many disadvantages, such as relatively large trauma, high chances of postoperative complications and long operation time,” wrote the authors of the review in the International Journal of Hyperthermia.

A recent study compared the effectiveness of open, laparoscopic, and robotic surgery in terms of outcomes and post-operative pregnancy success, and found that minimally invasive methods were best, according to a study published in JBRA Assisted Reproduction.

A study published in the BJOG: An International Journal of Obstetrics and Gynaecology reports a need for high-quality fibroid management and treatment guidelines.

A 4-year follow-up of a randomized control study comparing uterine artery embolization (UAE) to myomectomy for treating women with uterine fibroids has concluded that myomectomy achieves greater improvement in quality of life.

Uterine fibroids (UF) with heavy menstrual bleeding (HMB) pose a significant economic burden—mostly due to surgical and procedural costs and treatment, according to a claims analysis in the Journal of Women’s Health.

“Over 70% of women are estimated to develop uterine fibroids by age 50,” said senior author Irene Aninye, PhD, chief science officer for the Society for Women’s Health Research (SWHR) in Washington, D.C. “Fibroids are a complex condition that can range from being asymptomatic to having deleterious effects on a woman’s health and quality of life.”

Understanding the technology behind a newer uterus-sparing option for the management of uterine fibroids.

A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated. Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Autophagy is a controlled lysosomal degradation pathway that protects cells and allows to overcome cell death.

The authors noted that both primary options for treatment are currently being debated as to their efficacy and safety.

Many of the glaring disparities that exist in care for the 26 million women in the United States who suffer from uterine fibroids, which disproportionately affects up to 80% of Black women, are being aggressively addressed though a new multifaceted campaign called UNmuting Fibroids.

Vitamin D and green tea extract resulted in a significant reduction in the mean size of uterine fibroids among women of later reproductive age, according to a recent study.

A retrospective study that investigated the effectiveness and feasibility of fibroid enucleation in the anterior wall of the uterus by transverse uterine incision during cesarean section.

A study has once again validated ultrasound-guided high-intensity focused ultrasound (USgHIFU) as an effective technique to devascularize uterine fibroids.